Skip to main content
. 2023 Oct 4;6(12):e202301975. doi: 10.26508/lsa.202301975

Figure 6. MUC13 enhances metastatic potential of cancer cells.

Figure 6.

(A, B) In vivo metastasis (tail vein) caused by MUC13 overexpressing (SW480+MUC13) and non-overexpressing (SW480+Vector) cells. (A) (i, ii) Gross images of representative mouse with metastatic tumors and the three most affected organs—kidney, lung, and liver—are shown (i). MacroMETs and microMETs profiles of mice injected with overexpression of MUC13 compared with mice injected with vector cells in the kidneys and lungs. The data is represented as mean ± SEM. Sidak’s multiple comparison test is used after a two-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 denote significant differences (ii). (B) IHC analysis in lungs and kidney to demonstrate MUC13, YAP1, and β-catenin protein expression in metastatic lesions (scale bar, 50 μm). MacroMETs and microMETs profile of mice injected with overexpression of MUC13 compared with mice injected with vector cells in the kidneys and lungs.